Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
Posted 27 January 2015 | By Alexander Gaffney, RAC,
New guidance published by the US Food and Drug Administration (FDA) would bring the US into alignment with an international standard meant to ensure new drug products don't cause photosensitivity in patients.
The standard, S10 – Photosafety Evaluation of Pharmaceuticals, was developed by the International Conference on Harmonisation (ICH), an international body composed of FDA, the European Medicines Agency (EMA), Japan's Pharmaceutical and Medical Device Agency (PMDA) and pharmaceutical industry groups.
ICH guidelines, after undergoing a lengthy consultation process, are meant to be enacted in all member states, thereby making it easier for companies to make submissions in multiple regions using the same data.
"The purpose of this guidance is to recommend international standards for photosafety assessment, and to harmonize such assessments that support human clinical trials and marketing authorizations for pharmaceuticals," FDA explains in its guidance document. "It should reduce the likelihood that substantial differences in recommendations for photosafety assessment will exist among regions."
As Regulatory Focus has previously reported, the S10 guideline was previously released in draft form by FDA in February 2013. The standard outlines the testing requirements for companies to show their products don't cause photosensitivity—literally a reaction to light—in patients. Some drugs can cause phototoxicity, photoirritation or photoallergies in patients, all of which generally cause burns (similar to—or in some cases much worse than—sunburns experienced after a day at the beach).
Unlike other ICH documents covering photosafety, including the M3(R2) and S9 documents, S10 provides "specific information regarding testing strategies" for photosafety. For example, FDA notes that only products which absorb photons at wavelengths between 290 and 700 nm should be considered for safety testing.
The document goes into effect immediately, FDA said.
S10 – Photosafety Evaluation of Pharmaceuticals (FR)
Tags: Photosafety, S10, ICH, International Conference on Harmonization, Guidance, Final Guidance, Phototoxicity, Photosensitivity, Photoallergy
Regulatory Focus newsletters
All the biggest regulatory news and happenings.